Trial Profile
A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of FP253 in Combination With Fludarabine Phosphate.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs FP 253 (Primary) ; Fludarabine
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms FP253-GDEPT
- 08 Jul 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 24 Mar 2010 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 16 May 2008 Status changed from initiated to recruiting, as reported by ClinicalTrials.gov.